RE: Established path to market with this Ph3 trial24 Jan 2024 20:25
You could well be right it’s all a gamble, if they announce a partner deal on CIDP or ROW rights for Lupozor with an upfront cash payment that covers the next 2-3 years then this will do 400% minimum. Mcap will be above £50m during the next phase 3 trial I have no doubt about that, and two interim efficacy updates during the trial are huge catalysts that won’t be too far away especially once it gets going, I’m just greedy and want to time my entry well given I will be taking a large position even 5% difference is a lot in £ terms , if such news does come out I will wait for the dust to settle then take a large position higher, all a gamble, id say they have until end of Q1 to get some bonza news out so let’s see